Liquidia (NASDAQ:LQDA) CAO Sells 1,600 Shares

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 1,600 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $87.53, for a total transaction of $140,048.00. Following the completion of the transaction, the chief accounting officer directly owned 167,919 shares of the company’s stock, valued at $14,697,950.07. This trade represents a 0.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, July 13th, Dana Boyle sold 9,002 shares of Liquidia stock. The stock was sold at an average price of $71.51, for a total value of $643,733.02.

Liquidia Trading Down 0.0%

LQDA stock traded down $0.04 during midday trading on Wednesday, hitting $86.78. 1,140,996 shares of the company’s stock were exchanged, compared to its average volume of 1,805,184. The stock’s fifty day moving average price is $72.31 and its 200-day moving average price is $50.98. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The company has a market cap of $7.72 billion, a PE ratio of 619.90 and a beta of 0.55. Liquidia Corporation has a one year low of $16.82 and a one year high of $91.10.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. The firm’s revenue was up 4187.1% on a year-over-year basis. Research analysts predict that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LQDA shares. Wells Fargo & Company increased their target price on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. HC Wainwright set a $36.00 price target on shares of Liquidia in a research note on Friday, July 24th. Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a report on Friday, July 24th. Oppenheimer set a $75.00 price objective on shares of Liquidia in a research report on Friday, June 5th. Finally, Jefferies Financial Group restated a “buy” rating and set a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $86.18.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LQDA. Handelsbanken Fonder AB acquired a new stake in Liquidia in the 2nd quarter valued at approximately $1,993,000. Fulcrum Equity Management bought a new stake in Liquidia in the 2nd quarter valued at approximately $399,000. Fluent Financial LLC acquired a new position in Liquidia during the 2nd quarter worth approximately $287,000. FNY Investment Advisers LLC acquired a new position in Liquidia during the 2nd quarter worth approximately $1,395,000. Finally, Seven Fleet Capital Management LP grew its stake in shares of Liquidia by 124.5% during the 1st quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after acquiring an additional 113,609 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).